First real-world evidence of sparsentan efficacy in patients with IgA nephropathy treated with SGLT2 inhibitors
In this real-world setting, sparsentan shows a significant impact on proteinuria, leading to a relative reduction of 62% in UPCR after 14 weeks and beyond, even in patients already receiving SGLT2 inhibitors.
Authors
- Joerg Latus (ORCID: https://orcid.org/0000-0003-0584-4870)
- Leonie Kraft (ORCID: https://orcid.org/0000-0002-5821-893X)
- Severin Schricker (ORCID: https://orcid.org/0000-0002-6770-3056)
- S. Berger
- Tina Oberacker (ORCID: https://orcid.org/0000-0002-8887-1198)
- A. Schwab (ORCID: https://orcid.org/0000-0002-4576-558X)
- Moritz Schanz (ORCID: https://orcid.org/0000-0001-7300-8132)
- Claudia Seikrit
- Aline Zimmermann
- Bernd Hohenstein (ORCID: https://orcid.org/0000-0002-7306-3825)
Institutions
- Robert Bosch Hospital (DE)
- Nephrologisches Zentrum Villingen-Schwenningen (DE)
- PHV Dialysezentrum (DE)
- Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology (DE)
- Universitätsklinikum Aachen (DE)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Clinical Kidney Journal
- Published
- 2024-12-03
- DOI
- https://doi.org/10.1093/ckj/sfae394
- Citations
- 6
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.04